// App-Quantinova.ai

: - Gemcitabine plus nab-paclitaxel versus modified FOLFIRINOX as first line chemotherapy in metastatic pancreatic cancer: A comparison of toxicity and survival

Researchers

Presenter

  • V.Pacheco-Barcia

Principal Investigators

  • T.France

  • G.Zogopoulos

  • N.Bouganim

  • O.Donnay

  • T.Alcindor

  • R. MondejarSolos

  • K.Guo

  • E.Martin

  • R.Colomer

  • J.Asselah

Medical Centers

  • Hospital Universitario de la Princesa, Instituto de Investigacion Sanitaria la Princesa, Madrid, Spain

  • McGill University Health Center, Cedars Cancer Centre, Montreal, Quebec, Canada

  • McGill University Health Centre, Montreal, QC, Canada

  • McGill University Health Centre, Montreal, QC, Canada

  • Hospital Universitario La Paz, Madrid, Spain

  • McGill University Royal Institution, Montreal, Quebec, Canada

Locations

  • Spain

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Gemcitabine

  • Paclitaxel

  • FOLFIRINOX

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved